PRPO vs. TBIO, TLIS, AXDX, HLTH, OMIC, MEDS, OSA, IKT, BFRI, and NCNA
Should you be buying Precipio stock or one of its competitors? The main competitors of Precipio include Telesis Bio (TBIO), Talis Biomedical (TLIS), Accelerate Diagnostics (AXDX), Cue Health (HLTH), Singular Genomics Systems (OMIC), TRxADE HEALTH (MEDS), ProSomnus (OSA), Inhibikase Therapeutics (IKT), Biofrontera (BFRI), and NuCana (NCNA). These companies are all part of the "medical" sector.
Telesis Bio (NASDAQ:TBIO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, community ranking, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Precipio has lower revenue, but higher earnings than Telesis Bio. Precipio is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Telesis Bio had 5 more articles in the media than Precipio. MarketBeat recorded 8 mentions for Telesis Bio and 3 mentions for Precipio. Telesis Bio's average media sentiment score of 0.89 beat Precipio's score of 0.03 indicating that Precipio is being referred to more favorably in the news media.
Precipio received 263 more outperform votes than Telesis Bio when rated by MarketBeat users. Likewise, 73.32% of users gave Precipio an outperform vote while only 52.94% of users gave Telesis Bio an outperform vote.
Precipio has a net margin of -38.51% compared to Precipio's net margin of -183.66%. Telesis Bio's return on equity of -51.75% beat Precipio's return on equity.
Telesis Bio has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Precipio has a consensus target price of $40.00, suggesting a potential upside of 536.94%. Given Telesis Bio's higher possible upside, analysts clearly believe Precipio is more favorable than Telesis Bio.
37.6% of Telesis Bio shares are owned by institutional investors. Comparatively, 10.5% of Precipio shares are owned by institutional investors. 24.5% of Telesis Bio shares are owned by company insiders. Comparatively, 10.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Precipio beats Telesis Bio on 9 of the 16 factors compared between the two stocks.
Get Precipio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precipio Competitors List
Related Companies and Tools
